Csenge Advisory Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.73M | Buy |
154,984
+4,774
| +3% | +$125K | 0.15% | 130 |
|
|
2026
Q1 | $4.22M | Sell |
150,210
-2,180
| -1% | -$58K | 0.19% | 100 |
|
|
2025
Q4 | $3.79M | Buy |
152,390
+15,809
| +12% | +$399K | 0.17% | 109 |
|
|
2025
Q3 | $3.48M | Buy |
136,581
+48,137
| +54% | +$1.19M | 0.17% | 117 |
|
|
2025
Q2 | $2.08M | Buy |
88,444
+4,175
| +5% | +$97.4K | 0.11% | 155 |
|
|
2025
Q1 | $1.87M | Buy |
84,269
+45,214
| +116% | +$1.18M | 0.11% | 159 |
|
|
2024
Q4 | $1.04M | Sell |
39,055
-6,518
| -14% | -$177K | 0.06% | 260 |
|
|
2024
Q3 | $1.33M | Sell |
45,573
-1,327
| -3% | -$38.7K | 0.07% | 207 |
|
|
2024
Q2 | $1.31M | Buy |
46,900
+1,305
| +3% | +$35.9K | 0.07% | 199 |
|
|
2024
Q1 | $1.27M | Sell |
45,595
-3,370
| -7% | -$93.5K | 0.07% | 216 |
|
|
2023
Q4 | $1.41M | Sell |
48,965
-11,360
| -19% | -$343K | 0.09% | 187 |
|
|
2023
Q3 | $2M | Buy |
60,325
+4,208
| +7% | +$149K | 0.14% | 132 |
|
|
2023
Q2 | $2.06M | Sell |
56,117
-1,196
| -2% | -$46.6K | 0.14% | 122 |
|
|
2023
Q1 | $2.34M | Sell |
57,313
-78
| -0.1% | -$3.37K | 0.17% | 114 |
|
|
2022
Q4 | $2.94M | Buy |
57,391
+178
| +0.3% | +$8.53K | 0.23% | 81 |
|
|
2022
Q3 | $2.5M | Sell |
57,213
-3,291
| -5% | -$160K | 0.21% | 91 |
|
|
2022
Q2 | $3.17M | Buy |
60,504
+6,995
| +13% | +$356K | 0.27% | 77 |
|
|
2022
Q1 | $2.77M | Buy |
53,509
+3,876
| +8% | +$201K | 0.22% | 81 |
|
|
2021
Q4 | $1.96M | Buy |
49,633
+6,450
| +15% | +$320K | 0.17% | 107 |
|
|
2021
Q3 | $1.85M | Sell |
43,183
-6,450
| -13% | -$286K | 0.16% | 114 |
|
|
2021
Q2 | $1.96M | Buy |
49,633
+20,529
| +71% | +$798K | 0.17% | 107 |
|
|
2021
Q1 | $1.06M | Sell |
29,104
-8,213
| -22% | -$292K | 0.11% | 151 |
|
|
2020
Q4 | $1.37M | Sell |
37,317
-2,649
| -7% | -$97.2K | 0.16% | 102 |
|
|
2020
Q3 | $1.37M | Buy |
39,966
+1,227
| +3% | +$43K | 0.19% | 90 |
|
|
2020
Q2 | $1.2M | Buy |
38,739
+16,176
| +72% | +$550K | 0.17% | 103 |
|
|
2020
Q1 | $699K | Buy |
22,563
+6,573
| +41% | +$224K | 0.18% | 112 |
|
|
2019
Q4 | $594K | Buy |
15,990
+857
| +6% | +$30.5K | 0.15% | 136 |
|
|
2019
Q3 | $516K | Sell |
15,133
-8,213
| -35% | -$299K | 0.14% | 141 |
|
|
2019
Q2 | $959K | Buy |
23,346
+3,398
| +17% | +$135K | 0.33% | 57 |
|
|
2019
Q1 | $803K | Sell |
19,948
-10,560
| -35% | -$423K | 0.28% | 69 |
|
|
2018
Q4 | $1.26M | Buy |
30,508
+2,746
| +10% | +$114K | 0.46% | 45 |
|
|
2018
Q3 | $1.13M | Buy |
27,762
+12,945
| +87% | +$498K | 0.44% | 47 |
|
|
2018
Q2 | $510K | Sell |
14,817
-1,140
| -7% | -$39K | 0.19% | 116 |
|
|
2018
Q1 | $537K | Buy |
15,957
+3,518
| +28% | +$121K | 0.19% | 123 |
|
|
2017
Q4 | $427K | Buy |
+12,439
| New | +$424K | 0.15% | 121 |
|
Other funds holding PFE
Csenge Advisory Group's PFE Position: Q2 2026 in Review
Csenge Advisory Group increased its Pfizer (PFE) stake by 3.2% in Q2 2026, buying an estimated $125K and bringing the position to 154,984 shares worth $3.73M. The position accounts for 0.15% of the portfolio, ranked #130.
Csenge Advisory Group first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $4.22M in Q1 2026. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Csenge Advisory Group held 154,984 shares of Pfizer worth $3.73M as of Q2 2026.
- Csenge Advisory Group bought 4,774 Pfizer shares in Q2 2026, an estimated $125K.
- Pfizer made up 0.15% of Csenge Advisory Group's portfolio in Q2 2026, its #130 holding.
- Csenge Advisory Group first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Csenge Advisory Group's Pfizer position peaked at $4.22M in Q1 2026.
- 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.